Developer docs
API playgroundTry for free, no card

Search company profiles

B.More

Full company profile

uuid00041v4

Namestring
B.More
Legal namestring
B. More Inc.
Websiteurl
bmoreinc.org
Company typeenum
Private
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic medicine development, alcohol use disorder treatment, synthetic psilocybin research, addiction therapeutics, nonprofit biopharmaceutical
Industry3 codes
1Clinical Development (Phase I–III Trial Design & Execution)
CodeHLAIALAEPrimaryYes
2Regulatory Strategy & IND/NDA/BLA Submissions Support
CodeHLAIALAHPrimaryNo
3Outpatient Substance Use Disorder (SUD) Treatment Programs
CodeHLAFABADPrimaryNo
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Outpatient Mental Health and Substance Abuse Centers62142
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-Stage Psychedelic Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Nonprofit funding and donations
TypeLicensing Royalties
Description

As a 501(c)(3) nonprofit clinical-stage biopharmaceutical company, B. More is funded through charitable donations, grants, and philanthropy rather than commercial revenue. The company has invested millions of dollars over 10+ years in research.

bmoreinc.org
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

B. More is a clinical-stage non-profit biopharmaceutical company developing synthetic psilocybin drug candidates SYNP-101 and SYNP-102 combined with psychotherapy for the treatment of Alcohol Use Disorder (AUD), OCD, and other substance use disorders. The company has obtained FDA IND approval for a Phase 2b trial with 210 participants and is advancing toward commercialization as a prescription psychedelic medicine. Its research is conducted in partnership with NYU School of Medicine, with positive Phase 2a results showing an 83% average reduction in heavy drinking days.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 83% average reduction in heavy drinking days
+2 more records
Product overview1 text field

B. More is a clinical-stage, non-profit biopharmaceutical company developing a pipeline of synthetic psilocybin-based drug candidates (SYNP-101 and SYNP-102) for treating alcoholism (Alcohol Use Disorder) and other substance use disorders. The company's therapeutic approach combines psilocybin administration with psychotherapy, delivered through clinical trials conducted in partnership with NYU Langone Health and leading addiction researchers. The company is advancing toward FDA approval through Phase 2b trials for SYNP-102, building on positive proof-of-concept data showing significant reduction in heavy drinking.

Product and service3 records
1SYNP-101 (Synthetic Psilocybin)
CategoryDrug Candidate
Description

Synthetic psilocybin compound (SYNP-101) being investigated in clinical research for treatment of alcoholism (AUD) and other substance use disorders, currently undergoing Phase 2a proof-of-concept trials.

2SYNP-102 (Synthetic Psilocybin) Phase 2b
CategoryDrug Candidate
Description

Synthetic psilocybin formulation SYNP-102 in Phase 2b clinical trial for moderate to severe Alcohol Use Disorder (AUD), administered as a single 30mg dose combined with psychotherapy in a 210-participant randomized controlled trial.

3Psilocybin-Assisted Psychotherapy Program
CategoryTherapeutic Treatment Program
Description

Psychedelic-assisted psychotherapy treatment approach combining synthetic psilocybin administration with psychotherapy for alcoholism and substance use disorders. Demonstrated 83% average reduction in heavy drinking in Phase 2a trials and 48% total abstinence rate at 8 months versus 24% for placebo.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1NYU Langone Health / NYU School of Medicine
Strategic tierCoreTypeStrategic or Co-development Partner
Description

B. More partners with world-leading addiction researchers at NYU School of Medicine. The company provides clinical supplies and support for Dr. Michael Bogenschutz's work with AUD and OUD. Carey Turnbull serves as chair of the advisory board to NYU's Center for Psychedelic Medicine.

2Dr. Michael Bogenschutz
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Principal investigator leading B. More's psilocybin research program. Conducts clinical trials at NYU and UNM. Awarded $15 million NIDA grant for opioid use disorder study and NIAAA grant for AUD trial. B. More provides psilocybin clinical supplies for his studies.

bmoreinc.org
3Heffter Research Institute
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Carey Turnbull serves as board member and president of the Heffter Research Institute, a nonprofit dedicated to psychedelic research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

B.More

Clinical-Stage Psychedelic Biopharmaceuticalsbmoreinc.org

B.More firmographics

Firmographics
Name
B.More
Legal name
B. More Inc.
Website
https://bmoreinc.org
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

B.More industry classification

Industry
Product category
Clinical-Stage Psychedelic Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Outpatient Mental Health and Substance Abuse Centers (62142)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
akta.pro secondary industries
Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Outpatient Substance Use Disorder (SUD) Treatment Programs (HLAFABAD)

Keywords

  • Psychedelic medicine development
  • Alcohol use disorder treatment
  • Synthetic psilocybin research
  • Addiction therapeutics
  • Nonprofit biopharmaceutical

Where B.More is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

B.More business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Nonprofit funding and donations: As a 501(c)(3) nonprofit clinical-stage biopharmaceutical company, B. More is funded through charitable donations, grants, and philanthropy rather than commercial revenue. The company has invested millions of dollars over 10+ years in research.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

B.More product offering

Product offering

Core offering

B. More is a clinical-stage non-profit biopharmaceutical company developing synthetic psilocybin drug candidates SYNP-101 and SYNP-102 combined with psychotherapy for the treatment of Alcohol Use Disorder (AUD), OCD, and other substance use disorders. The company has obtained FDA IND approval for a Phase 2b trial with 210 participants and is advancing toward commercialization as a prescription psychedelic medicine. Its research is conducted in partnership with NYU School of Medicine, with positive Phase 2a results showing an 83% average reduction in heavy drinking days.

Product overview

B. More is a clinical-stage, non-profit biopharmaceutical company developing a pipeline of synthetic psilocybin-based drug candidates (SYNP-101 and SYNP-102) for treating alcoholism (Alcohol Use Disorder) and other substance use disorders. The company's therapeutic approach combines psilocybin administration with psychotherapy, delivered through clinical trials conducted in partnership with NYU Langone Health and leading addiction researchers. The company is advancing toward FDA approval through Phase 2b trials for SYNP-102, building on positive proof-of-concept data showing significant reduction in heavy drinking.

Differentiator

Problem solved

Functional benefit

Products and services

  • SYNP-101 (Synthetic Psilocybin) Synthetic psilocybin compound (SYNP-101) being investigated in clinical research for treatment of alcoholism (AUD) and other substance use disorders, currently undergoing Phase 2a proof-of-concept trials.
  • SYNP-102 (Synthetic Psilocybin) Phase 2b Synthetic psilocybin formulation SYNP-102 in Phase 2b clinical trial for moderate to severe Alcohol Use Disorder (AUD), administered as a single 30mg dose combined with psychotherapy in a 210-participant randomized controlled trial.
  • Psilocybin-Assisted Psychotherapy Program Psychedelic-assisted psychotherapy treatment approach combining synthetic psilocybin administration with psychotherapy for alcoholism and substance use disorders. Demonstrated 83% average reduction in heavy drinking in Phase 2a trials and 48% total abstinence rate at 8 months versus 24% for placebo.

Quantifiable outcome

  • 83% average reduction in heavy drinking days
  • +2 more outcomes

Companies that use B.More

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

B.More technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

B.More partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • NYU Langone Health / NYU School of MedicinecoreStrategic or Co-development PartnerB. More partners with world-leading addiction researchers at NYU School of Medicine. The company provides clinical supplies and support for Dr. Michael Bogenschutz's work with AUD and OUD. Carey Turnbull serves as chair of the advisory board to NYU's Center for Psychedelic Medicine.
  • Dr. Michael BogenschutzcoreStrategic or Co-development PartnerPrincipal investigator leading B. More's psilocybin research program. Conducts clinical trials at NYU and UNM. Awarded $15 million NIDA grant for opioid use disorder study and NIAAA grant for AUD trial. B. More provides psilocybin clinical supplies for his studies.
  • Heffter Research InstitutecoreStrategic or Co-development PartnerCarey Turnbull serves as board member and president of the Heffter Research Institute, a nonprofit dedicated to psychedelic research.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

B.More competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

B.More financial estimates

Financial estimate

Revenue estimate

Valuation estimate

B.More leadership team

Management profile

Number of profiles

Profiles5 records

B.More funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

B.More M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about B.More

What does B.More do?

B. More is a clinical-stage non-profit biopharmaceutical company developing synthetic psilocybin drug candidates SYNP-101 and SYNP-102 combined with psychotherapy for the treatment of Alcohol Use Disorder (AUD), OCD, and other substance use disorders. The company has obtained FDA IND approval for a Phase 2b trial with 210 participants and is advancing toward commercialization as a prescription psychedelic medicine. Its research is conducted in partnership with NYU School of Medicine, with positive Phase 2a results showing an 83% average reduction in heavy drinking days.

Is B.More a public or private company?

B.More is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was B.More founded?

B.More was founded in 2010. It employs 11 to 50 people.

Where is B.More based?

B.More is headquartered in New York, United States, in the North America region.

How does B.More make money?

One revenue line is on record: nonprofit funding and donations.

Does B.More have an API?

No public API is recorded for B.More.

What industry is B.More in?

B.More's product category is Clinical-Stage Psychedelic Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireB.More Receives FDA Investigational New Drug Approval for Psilocybin Alcohol Use Disorder Program Phase 2b Clinical TrialB.More Inc., a non-profit clinical-stage biopharmaceutical company, announced FDA approval of its Investigational New Drug application to begin a Phase 2b clinical trial evaluating synthetic psilocybin (SYNP-101) for treating alcohol use disorder. The randomized, double-blind, multicenter trial will enroll 226 participants and assess efficacy over 24 weeks, with Dr. Michael Bogenschutz of NYU Langone Center for Psychedelic Medicine serving as principal investigator and trial initiation planned for early 2023. The announcement follows promising Phase 2a results showing an 83% average reduction in alcohol consumption among heavy drinkers.PR NewswirePsychedelic Drug Therapy May Help Treat Alcohol AddictionA randomized controlled trial led by NYU Grossman School of Medicine found that two doses of psilocybin combined with psychotherapy reduced heavy drinking by 83% among alcohol-dependent participants over an eight-month period, compared with a 51% reduction in a placebo group receiving antihistamine. The study, published in JAMA Psychiatry on August 24, 2022, also found that nearly half of participants who received psilocybin stopped drinking entirely versus a quarter of the placebo group, marking the first placebo-controlled trial exploring psilocybin as a treatment for excessive alcohol consumption. The research team plans to conduct a larger multicenter trial under an FDA IND sponsored by B.More Inc., with the caveat that more work is needed to document the drug's effects and clarify dosing before widespread clinical use.